$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000114420413012065 Filed on February 28, 2013

Income Statement

Concept	2013 Q1	2012	2011 Q4
Revenue	$3.568M	$34.87M	$690.0K
YoY Change	-7.59%	315.81%	-91.0%
Cost Of Revenue	$971.0K	$8.144M	$400.0K
YoY Change	-26.44%	434.03%	-90.87%
Gross Profit	$2.997M	$26.28M	$290.0K
YoY Change	24.46%	1721.21%	-91.16%
Gross Profit Margin	84.0%	75.37%	42.03%
Selling, General & Admin	$2.103M	$9.763M	$8.390M
YoY Change	29.02%	40.88%	7.15%
% of Gross Profit	70.17%	37.15%	2893.1%
Research & Development	$7.754M	$36.67M	$760.0K
YoY Change	-12.35%	-3.05%	-88.81%
% of Gross Profit	258.73%	139.52%	262.07%
Depreciation & Amortization	$930.0K	$3.692M	$930.0K
YoY Change	0.0%	1.71%	4.49%
% of Gross Profit	31.03%	14.05%	320.69%
Operating Expenses	$9.857M	$46.43M	$9.150M
YoY Change	11.42%	22.77%	-24.57%
Operating Profit	-$4.429M	-$12.17M	-$8.860M
YoY Change	-26.97%	-66.68%	0.11%
Interest Expense	$110.0K	$550.0K	-$60.00K
YoY Change	-31.25%		-118.75%
% of Operating Profit
Other Income/Expense, Net	$108.0K	$554.0K
YoY Change		27600.0%
Pretax Income	-$4.320M	-$11.62M	-$8.910M
YoY Change	-26.78%	-68.19%	4.45%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.321M	-$11.62M	-$8.910M
YoY Change	-26.81%	-68.2%	4.45%
Net Earnings / Revenue	-121.1%	-33.32%	-1291.3%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.47	-$1.28	-$1.04
COMMON SHARES
Basic Shares Outstanding	93.50M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.90M	$54.40M	$27.00M
YoY Change	-8.11%	92.23%	-24.79%
Cash & Equivalents	$41.87M	$52.00M	$27.00M
Short-Term Investments		$2.400M
Other Short-Term Assets	$3.600M	$1.300M	$3.800M
YoY Change		-48.0%
Inventory	$5.773M	$4.000M	$279.0K
Prepaid Expenses			$235.0K
Receivables	$1.698M	$1.400M	$1.374M
Other Receivables	$3.553M	$0.00	$3.837M
Total Short-Term Assets	$52.89M	$61.20M	$32.49M
YoY Change	6.13%	88.31%	-29.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.71M	$16.30M	$18.27M
YoY Change	-10.29%	-10.93%	4.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.300M	$1.200M	$1.000M
YoY Change	18.18%	20.0%	11.11%
Total Long-Term Assets	$17.05M	$17.50M	$19.31M
YoY Change	-8.48%	-9.33%	4.97%
TOTAL ASSETS
Total Short-Term Assets	$52.89M	$61.20M	$32.49M
Total Long-Term Assets	$17.05M	$17.50M	$19.31M
Total Assets	$69.94M	$78.70M	$51.81M
YoY Change	2.16%	51.93%	-19.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.800M	$9.600M	$5.000M
YoY Change	-17.39%	23.08%	-20.63%
Accrued Expenses		$3.800M	$2.327M
YoY Change		11.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.41M	$25.80M	$18.69M
YoY Change	37.71%	37.97%	-1.1%
LONG-TERM LIABILITIES
Long-Term Debt	$2.700M	$0.00	$6.566M
YoY Change
Other Long-Term Liabilities	$51.80M	$56.30M	$6.566M
YoY Change	821.22%	-4.9%	-88.5%
Total Long-Term Liabilities	$51.82M	$56.30M	$59.19M
YoY Change	-9.41%	-4.9%	3.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.41M	$25.80M	$18.69M
Total Long-Term Liabilities	$51.82M	$56.30M	$59.19M
Total Liabilities	$76.23M	$82.10M	$77.88M
YoY Change	1.74%	5.39%	2.34%
SHAREHOLDERS EQUITY
Retained Earnings			-$172.0M
YoY Change
Common Stock			$145.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.283M	-$3.400M	-$26.08M
YoY Change
Total Liabilities & Shareholders Equity	$69.94M	$78.70M	$51.81M
YoY Change	2.16%	51.93%	-19.93%

Cashflow Statement

Concept	2013 Q1	2012	2011 Q4
OPERATING ACTIVITIES
Net Income	-$4.321M	-$11.62M	-$8.910M
YoY Change	-26.81%	-68.2%	4.45%
Depreciation, Depletion And Amortization	$930.0K	$3.692M	$930.0K
YoY Change	0.0%	1.71%	4.49%
Cash From Operating Activities	-$9.586M	$635.0K	-$6.610M
YoY Change	52.62%	-102.69%	-17.68%
INVESTING ACTIVITIES
Capital Expenditures	$642.0K	$2.068M	$710.0K
YoY Change	-20.74%	-63.75%	-31.73%
Acquisitions
YoY Change
Other Investing Activities	$47.00K	$138.0K	-$40.00K
YoY Change	11.9%	-16.36%	0.0%
Cash From Investing Activities	-$689.0K	-$2.286M	-$750.0K
YoY Change	-19.13%	-61.04%	-29.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$26.56M	20.00K
YoY Change		26.91%	-94.12%
NET CHANGE
Cash From Operating Activities	-$9.586M	$635.0K	-6.610M
Cash From Investing Activities	-$689.0K	-$2.286M	-750.0K
Cash From Financing Activities		$26.56M	20.00K
Net Change In Cash	-$10.28M	$24.91M	-7.340M
YoY Change	-155.72%	-392.64%	-16.21%
FREE CASH FLOW
Cash From Operating Activities	-$9.586M	$635.0K	-$6.610M
Capital Expenditures	$642.0K	$2.068M	$710.0K
Free Cash Flow	-$10.23M	-$1.433M	-$7.320M
YoY Change	44.24%	-95.11%	-19.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93497809
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012Q2	dei	Entity Public Float EntityPublicFloat	359000000	USD
CY2012	dei	Entity Registrant Name EntityRegistrantName	Protalix BioTherapeutics, Inc.
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Trading Symbol TradingSymbol	PLX
CY2012	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions		USD
CY2011	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	31000	USD
CY2010	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	9000	USD
CY2012	plx	Commitment Amount CommitmentAmount	1300000	USD
CY2012	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	3692000	USD
CY2011	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	3631000	USD
CY2010	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	3133000	USD
CY2012	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	177000	USD
CY2011	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	181000	USD
CY2010	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	174000	USD
CY2012	plx	Expected Definted Benefit Contribution During Period ExpectedDefintedBenefitContributionDuringPeriod	773000	USD
CY2012	plx	Expected Severance Liabilities Payments For Future Period ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod	963000	USD
CY2012Q4	plx	Forfeiture Rate ForfeitureRate	0.061
CY2012	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	7976000	USD
CY2011	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	6775000	USD
CY2010	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	7740000	USD
CY2012	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	1136000	USD
CY2011	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	1473000	USD
CY2010	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	2720000	USD
CY2012	plx	Number Of Subsidiaries NumberOfSubsidiaries	2
CY2012	plx	Other Gains Losses OtherGainsLosses	-446000	USD
CY2011	plx	Other Gains Losses OtherGainsLosses	-5418000	USD
CY2010	plx	Other Gains Losses OtherGainsLosses	4602000	USD
CY2012	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	25328000	USD
CY2011	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	20650000	USD
CY2010	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses		USD
CY2012	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	28689000	USD
CY2011	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	31043000	USD
CY2010	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	29951000	USD
CY2012	plx	Revenue Recognized Over Designated Period RevenueRecognizedOverDesignatedPeriod	4600000	USD
CY2012	plx	Revenue Recognized Period RevenueRecognizedPeriod	P14Y
CY2012Q4	plx	Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue	8600000	USD
CY2010Q4	plx	Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue	7800000	USD
CY2012	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	3139000	USD
CY2012	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts		USD
CY2011	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts	60000	USD
CY2010	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts		USD
CY2012	plx	Tax Rate Assumption Related To Deferred Tax Difference Reversal TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal	39%, 25% and 0%
CY2012Q4	plx	Withholding Tax Rate On Foreign Income WithholdingTaxRateOnForeignIncome	0.15
CY2012Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	11051000	USD
CY2011Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	7540000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5267000	USD
CY2011Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5032000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1410000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1374000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2032000	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2327000	USD
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1560000	USD
CY2011Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	89000	USD
CY2012Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1453000	USD
CY2011Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1221000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14786000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11148000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	180145000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	145814000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4612000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	886000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1282000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1780000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1410000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7751000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	886000	USD
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1282000	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7761168
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7469088
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7280469
CY2012	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2011	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10000	USD
CY2010	us-gaap	Asset Impairment Charges AssetImpairmentCharges	43000	USD
CY2012Q4	us-gaap	Assets Assets	78727000	USD
CY2011Q4	us-gaap	Assets Assets	51805000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	61170000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	32491000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52035000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27001000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35900000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81266000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	25034000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8899000	USD
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-45366000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93489809
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85630157
CY2012Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5175000
CY2011Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4000000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93489809
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85630157
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	93000	USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	86000	USD
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td>Concentration of credit risks and trade receivable</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">The Company's trade</font> receivable <font style="COLOR: black">represents mainly amounts to be received from Pfizer, as the Company currently receives most of its revenues from Pfizer. The Company does not require Pfizer to post collateral with respect to the receivables. The Company performs periodic credit evaluations of Pfizer's financial condition and believes there is no significant risk with respect to Pfizer's payment of the receivables.</font></p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif">  </p> <!--EndFragment--></div> </div>
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	8144000	USD
CY2011	us-gaap	Cost Of Revenue CostOfRevenue	1525000	USD
CY2010	us-gaap	Cost Of Revenue CostOfRevenue	4383000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9437000	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6121000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	48888000	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	50923000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	10449000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4746000	USD
CY2012Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6003000	USD
CY2011Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4119000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15176000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4579000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-647000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-149000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	363000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	305000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	192000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	164000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31536000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13764000	USD
CY2012	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	36000	USD
CY2011	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	14000	USD
CY2010	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	26000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1247000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1043000	USD
CY2012	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	670000	USD
CY2011	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	641000	USD
CY2010	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	531000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	127000	USD
CY2011	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-388000	USD
CY2010	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	589000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1748000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1108000	USD
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7000000	USD
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M6D
CY2012	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	554000	USD
CY2011	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2000	USD
CY2010	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	968000	USD
CY2012	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	171000	USD
CY2011	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-350000	USD
CY2010	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	591000	USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2011	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
CY2010	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9763000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6931000	USD
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6876000	USD
CY2012	us-gaap	Gross Profit GrossProfit	26280000	USD
CY2011	us-gaap	Gross Profit GrossProfit	1443000	USD
CY2010	us-gaap	Gross Profit GrossProfit	6861000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2977000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6147000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1029000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-243000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3891000	USD
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6860000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1281000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3005000	USD
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4563000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3760000	USD
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-910000	USD
CY2010	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1189000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	80000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1729000	USD
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves		USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	4039000	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	279000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2118000	USD
CY2011Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	279000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	192000	USD
CY2011Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves		USD
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	684000	USD
CY2011	us-gaap	Inventory Write Down InventoryWriteDown	363000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	82084000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	77882000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78727000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51805000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25755000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18693000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	56329000	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	59189000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5425000	USD
CY2011Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6566000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26558000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20927000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	501000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2286000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5868000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7992000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	635000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23570000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38464000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-11618000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-36529000	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-28998000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-12172000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-36531000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-29966000	USD
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	72500000	USD
CY2012Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3686000	USD
CY2011Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3837000	USD
CY2012	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	138000	USD
CY2011	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	165000	USD
CY2010	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	137000	USD
CY2012Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	USD
CY2011Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1400000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2068000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5705000	USD
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7855000	USD
CY2012Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2016000	USD
CY2011Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1700000	USD
CY2012	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	36000	USD
CY2011	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	14000	USD
CY2010	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	26000	USD
CY2012	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	276000	USD
CY2011	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	155000	USD
CY2010	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	377000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	251000	USD
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	235000	USD
CY2012	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	60000000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25400000	USD
CY2011Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20600000	USD
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2011	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2010	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1230000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	277000	USD
CY2010	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	501000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31096000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29419000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16310000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18271000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36665000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37818000	USD
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37691000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183595000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171977000	USD
CY2012	us-gaap	Revenues Revenues	34870000	USD
CY2011	us-gaap	Revenues Revenues	8386000	USD
CY2010	us-gaap	Revenues Revenues	6642000	USD
CY2012Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2011Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.5
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3357000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-26077000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-11323000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	15883000	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25388000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20590000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1199000	USD
CY2012	us-gaap	Severance Costs SeveranceCosts	1000000	USD
CY2011	us-gaap	Severance Costs SeveranceCosts	816000	USD
CY2010	us-gaap	Severance Costs SeveranceCosts	1100000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	7751000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	886000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	1282000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	3208
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2010	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y9M18D
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0323
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	9741655
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	11341655
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	176986
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19700000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	299000	USD
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	510000	USD
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td>Use of estimates in the preparation of financial statements</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif">  </p> <!--EndFragment--></div> </div>
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90845901
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84645364
CY2010	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80960300

Files In Submission

Name	View Source	Status
0001144204-13-012065-index-headers.html	Edgar Link	pending
0001144204-13-012065-index.html	Edgar Link	pending
0001144204-13-012065.txt	Edgar Link	pending
0001144204-13-012065-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
plx-20121231.xml	Edgar Link	completed
plx-20121231.xsd	Edgar Link	pending
plx-20121231_cal.xml	Edgar Link	unprocessable
plx-20121231_def.xml	Edgar Link	unprocessable
plx-20121231_lab.xml	Edgar Link	unprocessable
plx-20121231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlogo.jpg	Edgar Link	pending
tlogoex23-1.jpg	Edgar Link	pending
tpg06.jpg	Edgar Link	pending
tpg17.jpg	Edgar Link	pending
tpg17a.jpg	Edgar Link	pending
tpg19.jpg	Edgar Link	pending
tpg19a.jpg	Edgar Link	pending
tpg57.jpg	Edgar Link	pending
v334254_10k.htm	Edgar Link	pending
v334254_ex23-1.htm	Edgar Link	pending
v334254_ex3-6.htm	Edgar Link	pending
v334254_ex31-1.htm	Edgar Link	pending
v334254_ex31-2.htm	Edgar Link	pending
v334254_ex32-1.htm	Edgar Link	pending
v334254_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2013 Q1 Form 10-K Financial Statement

#000114420413012065 Filed on February 28, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2013 Q1 Form 10-K Financial Statement

#000114420413012065 Filed on February 28, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx